Drugmakers and PBMs drive up insulin prices, California says
California has accused Eli Lilly, Sanofi and Novo Nordisk of individually conspiring with major pharmacy benefit managers and abusing their market power to drive up the price of insulin.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10